Cellular Origins and Fresenius Kabi, an operating company of Fresenius, have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs) with the goal of digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation. This work aims to assist cell therapy developers in manufacturing their therapies at scale using their preferred processing tools.
 
This collaboration will allow Cellular Origins and Fresenius Kabi to harness the experience of both teams to work toward the physical and digital integration of the Cue system within Constellation. Bolstering Constellation’s capabilities with fully automated cell processing will enable end users to improve production efficiencies while also reducing inconsistencies by alleviating the risk of human variation and error.
 
Following the focus on Cue, the collaboration contemplates focusing on Fresenius Kabi’s wider cell therapy technologies portfolio, including the Lovo Cell Processing System and future products currently in development.
 
“Cellular Origins has developed Constellation to enable fully industrialized manufacture of cell and gene therapies,” said Dr Edwin Stone, CEO at Cellular Origins. “Forming strong collaborations is essential to ensuring the industry can implement the transformative power of automation whilst using the tools that are best for the biology and, therefore, for patients. Fresenius Kabi is an industry-leading developer of automated technologies to support the production of cell therapies. This is why we are working closely with their team to unlock the power of automation throughout the entire manufacturing process, with the goal of bringing life-saving therapies to patients, faster and more affordably.”
 
“For Fresenius Kabi, automation is crucial to addressing some of the biggest research and manufacture challenges in our industry. This is a major reason for our collaboration with Cellular Origins,” said Dr Christian Hauer, President MedTech at Fresenius Kabi. “Our cell therapy technologies are designed with automation at their core, to provide new levels of precision and efficiency. By working closely with the team at Cellular Origins, we hope to advance the CGT industry by helping therapy developers embrace automation during the production process with the goal of ultimately benefitting patients.”